Navigation Links
YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Date:12/12/2008

ain partnership revenues.

About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide. The Company is developing nimotuzumab, a humanized monoclonal antibody, and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and chemotherapy. The drug, which is approved for marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,000 patients treated worldwide, to date, no Grade III/IV rash or radiation dermatitis has been reported and reports of any of the other side-effects that are typical of EGFR-targeting molecules have been rare. AeroLEF(R) is in development for the treatment of moderate to severe pain, including cancer pain. The product completed a randomized trial in 2007 and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual repo
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
5. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
6. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  In part four ... leverage a hospital pharmacy as a strategic asset, ... practice leader for Cardinal Health,s Innovation Delivery Solutions business, ... can benefit both hospitals and patients. "Every ... one part of their job in a value-based healthcare ...
(Date:8/29/2014)... August 29, 2014 Pixcelldata, the ... software has announced a major new deal with Dutch ... renowned pathology expert, Dr. Marius Nap . ... 26th European Congress of Pathology which is taking placing ... Arena, London where Pixcelldata will ...
(Date:8/28/2014)... Reportlinker.com announces that a new market ... North America Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America Aesthetic Lasers ... Summary GlobalData,s new report, "North America Aesthetic ... provides key market data on the North America ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that ... upcoming investor conferences:   Kathryn Falberg, the ... ROTH 23rd Annual OC Growth Stock Conference in Dana Point, ... Time Bruce Cozadd, the company,s chairman and chief executive ...
... DUBLIN, March 8, 2011 Warner Chilcott plc (Nasdaq: ... of 25 million of its ordinary shares by certain ... Bain Capital Partners, J.P. Morgan Partners (advised by CCMP ... of the Company,s senior management. The offering is being ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe is ... Chuang, has joined their practice. Dr. Chuang garners extensive ... specializes in minimally-invasive arthroscopic and reconstructive treatments of the ... for patients with general and sports-related orthopedic needs. ... the medical field. As an Orange County native, he ...
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... research group of Dr. John Lewis at the University of ... ON) has confirmed that "invadopodia" play a key role in ... Reports , shows preventing these tentacle-like structures from forming can ... in 5 Canadians will develop cancer in their lifetime, and ... In 2014, it,s estimated that nine Canadians will die of ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2
... in police custody is standard operating procedure for many ... idea that using a Taser could lead to a ... final results of a study conducted by emergency medicine ... Medical Center showed no lasting effects of the Taser ...
... Some ethnic minorities could be twice as likely as ... prayer to medication for treating depression , according ... Asians who took the survey were skeptical about the ... to antidepressants, according to Jane Givens, M.D., of Boston ...
... liberated woman is certainly looking for ways and means of ... available is a bit complicated . ,Offering a ... Lybrel and the Food and Drug Administration (FDA) is expected ... meant to evoke "liberty," would be the fourth new oral ...
... traditional Indigenous land owners could help improve the overall ... ,Over the past 30 years, there has ... people who regain ownership and control of their traditional ... Research Fellow at the Jumbunna Indigenous House of Learning, ...
... the risk of diabetes in the Indigenous population, say ... Robyn McDermott, Pro-vice Chancellor of the Division of Health ... while clinical care of adults with diabetes has improved, ... ,The results, published in the latest Medical Journal ...
... the myth of big hydropower projects being clean, a ... the country are accountable for at least 19 ... ,According to the study, Indian dams are larger ... large dams could be around 33.5 million tonnes (MT) ...
Cached Medicine News:Health News:Healthy Humans Not Harmed By Taser 2Health News:Minorities Prefer Counseling and Prayer to Drugs for Treating Depression 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 2Health News:New Pill to Suppress Menstrual Bleeding Indefinitely 3Health News:Health Benefits Of Traditional Land Ownership 2
... Immunoassay Plus Control is a ... in today's busy immunoassay laboratory. ... this human serum based control ... separate control products for immunoassay ...
... The Vidiera NsD Nucleic Sample Detection ... acids, post amplification. The new platform ... by capillary electrophoresis (CE), with software features ... and flexibility. Vidiera NsD has the ...
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... PLUS CONCENTRATOR ANALYZER Now there is one ... parameters necessary for performing concentrator checks. Introducing ... efficient and cost-effective analyzer designed with technicians ... flow rate (L-min), and patient outlet pressure ...
Medicine Products: